A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background/aims Patients with primary sclerosing cholangitis (PSC) have an increased risk of developing cholangiocarcinoma (CC), which is notoriously difficult to diagnose since these patients may have increased levels of bilirubin due to benign strictures. To evaluate the validity of different tumor markers as an aid to diagnosing CC, we have carried out serial serum tumor marker analyses in patients with PSC who have been followed for several years.Methods Seventy-five patients with PSC, without any clinical signs of CC were included in the study. They were investigated every 6th months for 3 years, with extensive liver function tests and four tumor serum markers CEA, CA 19-9, CA 50 and CA 242. The patients were then followed for 5 years to exclude the possibility that CC remained unrecognized.Results Of the 75 patients, two (3%) developed CC during the 3-year period. One of these had normal levels, and one had significantly increased levels of the tumor markers. In the follow-up part of the study two further patients died from CC and one from hepatocellular carcinoma, 3 and 4 years after the 3-year study, respectively. Twenty-one patients had an increase of one of the markers on at least one occasion. Five patients had a transient increase of more than double the upper normal limit of the tumor markers on more than one occasion. There was a good correlation between CA 19-9, CA 50 and CA 242, but not with CEA. Fourteen of the 75 patients had periods of increased bilirubin levels, but none of these showed increased tumor markers.Conclusions The serum tumor markers CEA, CA 19-9, CA 50 and CA 242 are of limited value for the detection of CC in patients with PSC because of low specificity. However, we found no falsely increased values in patients with hyperbilirubinemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CA 19-9 is therefore an inadequate marker for regular surveillance in PSC.124,125,[127][128][129]”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [124]
In the citing paper
“Longitudinal series with repeated measures of CA 19-9 are contradictory 124,125 and increased levels are common in benign disease.126”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [124]
In the citing paper
“They are of limited diagnostic sensitivity and specificity, either alone or in combination.124,126,128,301,302”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [124]
Citations
Cites
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
Self-citationPrimary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
Wiesner, R. H., Grambsch, P. M., Dickson, R. E., Ludwig, J., Maccarty, R. L., Hunter, E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J., & Larusso, N. F. (1989) · Hepatology · doi:10.1002/hep.1840100406 · Cited by 643
Natural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Liver Transplantation for Malignant Disease: Results in 93 Consecutive Patients
OʼGRADY, J. G., POLSON, R. J., ROLLES, K., CALNE, R. Y., & WILLIAMS, R. (1988) · Annals of Surgery · doi:10.1097/00000658-198804000-00002 · Cited by 446
Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis
ROSEN, C. B., NAGORNEY, D. M., WIESNER, R. H., COFFEY, R. J., & LARUSSO, N. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199101000-00004 · Cited by 391
Bergquist, A., Glaumann, H., Persson, B., & Broomé, U. (1998) · Hepatology · doi:10.1002/hep.510270201 · Cited by 281
Self-citationSerum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279
Primary sclerosing cholangitis: Refinement and validation of survival models
Dickson, E. R., Murtaugh, P. A., Wiesner, R. H., Grambsch, P. M., Fleming, T. R., Ludwig, J., LaRusso, N. F., Malinchoc, M., Chapman, R. W., Kaplan, M. M., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91449-e · Cited by 270
Orthotopic Liver Transplantation for Primary Sclerosing Cholangitis
MARSH, J. W., IWATSUKI, S., MAKOWKA, L., ESQUIVEL, C. O., GORDON, R. D., TODO, S., TZAKIS, A., MILLER, C., THIEL, D. V., & STARZL, T. E. (1988) · Annals of Surgery · doi:10.1097/00000658-198801000-00005 · Cited by 253
NICHOLS, J. C., GORES, G. J., LARUSSO, N. F., WIESNER, R. H., NAGORNEY, D. M., & RITTS, R. E. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60696-x · Cited by 214
Research works printed but not linked: 1
- Pagnuzzi, 1988, CA 19–9 and CA 50 in benign and malignant pancreatic and biliary disease, Cancer, 61, 2100, 10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z · doi:10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z
Cited by
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Khan, S. A., Davidson, B. R., Goldin, R. D., Heaton, N., Karani, J., Pereira, S. P., Rosenberg, W. M. C., Tait, P., Taylor-Robinson, S. D., Thillainayagam, A. V., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301748 · Cited by 797
“%) developed CC.”
BackgroundInfluentialGuidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Khan, S. A., Davidson, B. R., Goldin, R., Pereira, S. P., Rosenberg, W. M. C., Taylor-Robinson, S. D., Thillainayagam, A. V., Thomas, H. C., Thursz, M. R., & Wasan, H. (2002) · Gut · doi:10.1136/gut.51.suppl_6.vi1 · Cited by 648
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
“However, other investigators have questioned the utility of this tumor marker in predicting development of cholangiocarcinoma or other pancreaticobiliary tumors due to a high falsepositivity rate (11, 18, 19).”
Background
Metadata
- Authors
- Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U.
- Affiliations
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- University Hospital of Umeå (SE)
- Örebro University Hospital (SE)
- Uppsala University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Hultcrantz, Rolf
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 30
- Issue
- 4
- Pages
- 669-673
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2155936309
- Cited by
- 107
- References
- 31
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2019: 2 · 2017: 4 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 4
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- cholangiocarcinoma, primary sclerosing cholangitis, serum tumor markers, CA19-9, CA50, CA242, carcinoembryonic antigen, cancer detection, hyperbilirubinemia, benign biliary strictures, hepatocellular carcinoma, cancer screening
- MeSH terms
- Adult, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoembryonic Antigen, Colchicine, Double-Blind Method, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Cholangitis, Sclerosing, Antigens, Tumor-Associated, Carbohydrate, Cholangiocarcinoma, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/s0168-8278(99)80198-6
- The paper
- Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U. (1999). A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(99)80198-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.